McDermott and Bull executive Search
 

Other News

Acasti Issues Shares in Settlement of Claims with Former Chief Executive Officer

Financial by 0 comments

LAVAL, Québec, May 23, 2019 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has completed the previously disclosed issuance of 900,000 common shares from treasury to its former chief executive officer (the “Former CEO”) pursuant to the terms of a settlement agreement […]

Continue Reading →

Acute Myocardial Infarction Patients Treated Early With Cell Therapy Delivered With BioCardia’s Helix Endocardial Delivery System Improved in Ejection Fraction and NYHA Class

Coronary/Structural Heart by 0 comments

PARIS and SAN CARLOS, Calif., May 23, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced positive results from a study of the company’s Helix™ Biotherapeutic Delivery System for cell therapy used to treat patients early following acute myocardial infarction (AMI) […]

Continue Reading →

Robocath strengthens its medical advisory board with international interventional cardiology experts

Financial by 0 comments

Rouen, France, May 21, 2019 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that Pr Haude, Dr Lorgat and Pr Nef have joined its medical advisory board. All are global experts and recognized leaders in interventional cardiology. The board […]

Continue Reading →

Elixir Medical Announces Outstanding 9 and 12-Month Clinical and Imaging Results for the Transformational DynamX™ Bioadaptor at EuroPCR

Coronary/Structural Heart by 0 comments

MILPITAS, Calif. & PARIS–(BUSINESS WIRE)–Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced at EuroPCR excellent 9 and 12-month clinical and imaging data for the DynamX™ Novolimus-eluting Bioadaptor System, a next-generation coronary intervention system designed to treat blocked arteries via a novel vessel […]

Continue Reading →

Use of HeartFlow Planner Leads to Change in Treatment Strategy in Nearly Half of Patients with Coronary Heart Disease

Coronary/Structural Heart by 0 comments

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., today announced new data demonstrating that the use of the investigational HeartFlow Planner, a real-time, non-invasive interactive planning tool, led to a change in treatment strategy in 45% of patients with coronary artery disease (CAD) and reduced the need for invasive physiology. The data from […]

Continue Reading →

Corindus CorPath GRX System Successfully Used in Live Complex Robotic-Assisted Coronary Intervention at EuroPCR 2019

Coronary/Structural Heart by 0 comments

WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today its CorPath® GRX System was successfully used to perform a live complex robotic-assisted percutaneous coronary intervention (PCI) at the EuroPCR 2019 Conference in Paris, France on Wednesday, May 22, 2019. Interventional Cardiologist, […]

Continue Reading →

Orchestra BioMed™ Presents Clinical Data at EuroPCR 2019 Demonstrating Safety and Efficacy of BackBeat Cardiac Neuromodulation Therapy (CNT)

Rhythm by 0 comments

Novel implantable bioelectronic treatment delivers immediate, substantial, and sustained reduction in blood pressure Data showed 14.2 mmHg reduction in 24-hour ambulatory systolic blood pressure at three months and 23.4 mmHg reduction in office cuff systolic blood pressure out to two years Therapy applicable to a wide range of hypertensive patients […]

Continue Reading →

BioSig Allowed First Key US Patent Claims for its PURE EP™ System

Rhythm by 0 comments

Santa Monica, CA, May 23, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the US Patent Office allowed 33 patent claims covering its PURE EP™ System. […]

Continue Reading →

Economic Analysis Shows ACIST CVi™ System Significantly Reduces Costs and Improves Patient Safety for Coronary Catheterizations Compared with Manual Injection

Coronary/Structural Heart by 0 comments

EDEN PRAIRIE, Minn., May 22, 2019 /PRNewswire/ — ACIST Medical Systems, a pioneering interventional and diagnostic technology company with a portfolio of advanced products for the cardiac cath lab, today announced the results of an economic analysis demonstrating the ACIST CVi contrast delivery system significantly reduces costs, increases operational efficiency and improves patient […]

Continue Reading →
1 2 3 … 258